Vitamin D compounds for people with chronic kidney disease not requiring dialysis (Q24240439)

1

0 references

Jonathan Craig

Jonathan C Craig

3

0 references

Giovanni Strippoli

6

Giovanni FM Strippoli

0 references

Grahame Elder

4

Grahame Elder

0 references

David McGregor

2

Cochrane Database of Systematic Reviews

David O McGregor

0 references

publication date

7 October 2009

0 references

published in

0 references

cites work

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Effect of dialysis dose and membrane flux in maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Serum phosphate levels and mortality risk among people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Association of activated vitamin D treatment and mortality in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Proximal muscle weakness in uremia. Case reports and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Impact of kidney bone disease and its management on survival of patients on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Interventions for preventing bone disease in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Vitamin D analogues for the treatment and prevention of bone disease in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Association of oral calcitriol with improved survival in nondialyzed CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Chronic renal failure and vitamin d metabolites: A status report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Mortality risk among hemodialysis patients receiving different vitamin D analogs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Increased risk of hip fracture among patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Ventricular-arterial coupling in a rat model of reduced arterial compliance provoked by hypervitaminosis D and nicotine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Decreased Renal Function in Association with Administration of 1,25-Dihydroxyvitamin D3 to Patients with Stable, Advanced Renal Failure1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Low dose calcitriol versus placebo in patients with predialysis chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021

Meta-analysis: vitamin D compounds in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008175

7 January 2021